Showing results (11-20 of 46) with videos related to
Sort By:
Pageof 5
ACS Omega|October 23, 2023
Characterization of Structurally Diverse <sup>18</sup>F-Labeled d-TCO Derivatives as a PET Probe for Bioorthogonal Pretargeted ImagingKaruna Adhikari, Jonatan Dewulf, Christel Vangestel, et al.Cancer Biotherapy & Radiopharmaceuticals|December 6, 2022
<sup>18</sup>F-FDG and <sup>18</sup>F-FLT Uptake Profiles for Breast Cancer Cell Lines Treated with Targeted PI3K/Akt/mTOR TherapiesYanina Dockx, Christel Vangestel, Sven De Bruycker, et al.The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|July 13, 2019
Bone metastases in the era of targeted treatments: insights from molecular biologyJonatan Dewulf, Christel Vangestel, Yannick Verhoeven, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 8, 2018
<sup>18</sup>F-Flortanidazole Hypoxia PET Holds Promise as a Prognostic and Predictive Imaging Biomarker in a Lung Cancer Xenograft Model Treated with Metformin and RadiotherapySven De Bruycker, Christel Vangestel, Tim Van den Wyngaert, et al.Molecular Imaging and Biology|June 22, 2016
Evaluation of [<sup>18</sup>F]Fluorothymidine as a Biomarker for Early Therapy Response in a Mouse Model of Colorectal CancerSara Rapic, Christel Vangestel, Jeroen Verhaeghe, et al.Molecular Imaging and Biology|April 22, 2015
Characterization of [(99m)Tc]Duramycin as a SPECT Imaging Agent for Early Assessment of Tumor ApoptosisFilipe Elvas, Christel Vangestel, Sara Rapic, et al.Molecular Imaging|June 11, 2021
Early Changes in [<sup>18</sup>F]FDG Uptake as a Readout for PI3K/Akt/mTOR Targeted Drugs in HER-2-Positive Cancer XenograftsYanina Dockx, Christel Vangestel, Tim Van den Wyngaert, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 24, 2016
<sup>99m</sup>Tc-Duramycin SPECT Imaging of Early Tumor Response to Targeted Therapy: A Comparison with <sup>18</sup>F-FDG PETFilipe Elvas, Jan Boddaert, Christel Vangestel, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 3, 2011
(99)mTc-(CO)(3) His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumabChristel Vangestel, Christophe Van de Wiele, Nancy Van Damme, et al.Molecular Imaging and Biology|January 6, 2016
Baseline [(18)F]FMISO μPET as a Predictive Biomarker for Response to HIF-1α Inhibition Combined with 5-FU Chemotherapy in a Human Colorectal Cancer Xenograft ModelSven De Bruycker, Christel Vangestel, Tim Van den Wyngaert, et al.Pageof 5